SLC5A2 and breast carcinoma: In the context of cancer, SGLT2 overexpression was found in prostate cancer, pancreatic and lung adenocarcinoma, glioblastoma, and breast cancer [62], and recently, investigators have also begun to study the potential of SGLT2 inhibitors in preclinical cancer studies [63].